Harvard Bioscience (NASDAQ:HBIO) Coverage Initiated by Analysts at Zacks Research

Stock analysts at Zacks Research began coverage on shares of Harvard Bioscience (NASDAQ:HBIO) in a research report issued to clients and investors on Tuesday, Zacks reports. The firm set a “hold” rating on the medical instruments supplier’s stock.

A number of other brokerages have also weighed in on HBIO. Weiss Ratings lowered shares of Harvard Bioscience from a “sell (d-)” rating to a “sell (e+)” rating in a report on Friday, August 14th. Benchmark boosted their price objective on shares of Harvard Bioscience from $6.00 to $7.50 and gave the company a “speculative buy” rating in a research note on Wednesday, August 12th. One research analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, Harvard Bioscience currently has a consensus rating of “Hold” and a consensus price target of $6.75.

Harvard Bioscience Stock Performance

NASDAQ HBIO opened at $8.61 on Tuesday. Harvard Bioscience has a 12 month low of $4.00 and a 12 month high of $9.10. The company has a quick ratio of 0.98, a current ratio of 1.87 and a debt-to-equity ratio of 4.94. The company has a 50-day moving average of $8.19 and a 200-day moving average of $6.47.

Harvard Bioscience (NASDAQ:HBIO) last released its earnings results on Tuesday, August 11th. The medical instruments supplier reported ($0.14) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.21) by $0.07. Harvard Bioscience had a negative net margin of 11.86% and a negative return on equity of 33.13%. The business had revenue of $22.73 million for the quarter, compared to analysts’ expectations of $21.45 million. On average, analysts anticipate that Harvard Bioscience will post -2.44 earnings per share for the current year.

Institutional Trading of Harvard Bioscience

A hedge fund recently bought a new stake in Harvard Bioscience stock. Citadel Advisors LLC purchased a new stake in shares of Harvard Bioscience, Inc. (NASDAQ:HBIO) during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund purchased 13,251 shares of the medical instruments supplier’s stock, valued at approximately $81,000. Citadel Advisors LLC owned approximately 0.29% of Harvard Bioscience as of its most recent SEC filing. 80.87% of the stock is owned by hedge funds and other institutional investors.

Key Headlines Impacting Harvard Bioscience

Here are the key news stories impacting Harvard Bioscience this week:

• Neutral Sentiment: Sidoti forecasts a gradual improvement, with estimated losses of $2.44 per share in 2026 and $1.15 in 2027, followed by positive EPS of $0.43 in 2028. The outlook suggests a potential longer-term recovery, but the articles do not indicate that these estimates were revisions. MarketBeat Harvard Bioscience coverage
• Neutral Sentiment: CEO John Duke and CFO Mark Frost are scheduled to participate in Canaccord Genuity’s MedTech, Diagnostics, and Digital Health and Services Forum on November 11. No new financial or operating information was disclosed in the announcement. Forum participation announcement

About Harvard Bioscience

Harvard Bioscience, Inc (NASDAQ: HBIO) develops, manufactures and supplies specialized tools, equipment and consumables used in biomedical research, drug discovery and related life science applications. Its products support work in areas such as cell biology, electrophysiology, gene delivery, organ-on-chip research and preclinical studies.

The company’s portfolio includes laboratory instruments, tissue and organ perfusion systems, electrophysiology equipment, cell and molecular biology products, and related consumables.